SCHEMBL3395331

SCHEMBL3395331

CC(Cl)C(=O)c1ccc(CC(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.50
CAMK2A Q9UQM7 1/20 0.50
AKR1B1 P15121 1/20 0.48
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ABCC4 O15439 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
PTGS1 P23219 1/20 0.47
HTT P42858 1/20 0.47
SRD5A2 P31213 2/20 0.45
KLKB1 P03952 1/20 0.44
CTSB P07858 1/20 0.44
NR1H4 Q96RI1 4/20 0.44
EPHX2 P34913 1/20 0.44
ANPEP P15144 1/20 0.43
ENPEP Q07075 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11668645 0.86 CA2 (0.52) CA2CAMK2AAKR1B1ALDH1A1HPGD
SCHEMBL2970528 0.83 CA2 (0.48) CA2CAMK2AAKR1B1ALDH1A1HPGD
SCHEMBL9518384 0.81 PTGS1 (0.50) ALDH1A1HPGDLMNATSHRPTGS1
SCHEMBL10716596 0.77 ATM (0.55) ALDH1A1LMNAGAATSHR
SCHEMBL2329814 0.77 ATM (0.55) ALDH1A1LMNAGAATSHR
SCHEMBL13232550 0.77 HDAC1 (0.35) ALDH1A1HPGDHSD17B10LMNATSHR
SCHEMBL10838346 0.77 ALDH1A1 (0.56) ALDH1A1HPGDHSD17B10
SCHEMBL10978746 0.76 CA2 (0.54) CA2CAMK2AAKR1B1ALDH1A1HPGD
SCHEMBL28872737 0.76 ANPEP (0.55) CA2CAMK2AAKR1B1ALDH1A1HPGD
SCHEMBL69614 0.76 CA2 (0.79) CA2CAMK2AAKR1B1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3415171-B1 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-12-14 EP claimed
EP-3415171-A1 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE KCI Licensing, Inc. (US) 2018-12-19 EP claimed
EP-2244748-A2 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE KCI Licensing, Inc. (US) 2010-11-03 EP claimed
WO-2009108884-A2 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE KCI LICENSING INC. (US) 2009-09-03 WO claimed
US-20090216170-A1 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2009-08-27 US claimed
US-5482719-A Drug delivery systems MEDIPRO SCIENCES LIMITED (CA) 1996-01-09 US claimed
WO-1994009826-A2 DRUG DELIVERY SYSTEMS, CHARACTERISED BY A PHOTOLABILE LINKAGE MEDIPRO SCIENCES LIMITED (CA) 1994-05-11 WO claimed
EP-4572795-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS The University of Chicago (US) 2025-06-25 EP disclosed
US-20250122502-A1 Bifunctional Molecules and Methods of Using Thereof FLAGSHIP PIONEERING, INC. (US) 2025-04-17 US disclosed
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION THE JOHNS HOPKINS UNVERSITY 2025-04-10 US disclosed
US-20240400684-A1 ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-12-05 US disclosed
WO-2024040169-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS THE UNIVERSITY OF CHICAGO (US) 2024-02-22 WO disclosed
US-20230332145-A1 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF FLAGSHIP PIONEERING, INC. (US) 2023-10-19 US disclosed
EP-2244748-A2 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE KCI Licensing, Inc. (US) 2010-11-03 EP disclosed
WO-2009108884-A2 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE KCI LICENSING INC. (US) 2009-09-03 WO disclosed
US-20090216170-A1 SYSTEM AND METHOD FOR HEALING A WOUND AT A TISSUE SITE SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2009-08-27 US disclosed
US-5726243-A Mild solid-phase synthesis of aligned, branched triple-helical peptides REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1998-03-10 US disclosed
US-5576419-A Mild solid-phase synthesis of aligned branched triple-helical peptides REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1996-11-19 US disclosed
US-5482719-A Drug delivery systems MEDIPRO SCIENCES LIMITED (CA) 1996-01-09 US disclosed
WO-1994009826-A2 DRUG DELIVERY SYSTEMS, CHARACTERISED BY A PHOTOLABILE LINKAGE MEDIPRO SCIENCES LIMITED (CA) 1994-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION OPRM1, OPRK1, OPRL1 CA2 4595/4885CAMK2A 1048/4885AKR1B1 2741/4885
US-20230332145-A1 BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF EFTUD2, DDX21, SNRPE CA2 4173/4885CAMK2A 3105/4885AKR1B1 4068/4885
US-20250122502-A1 Bifunctional Molecules and Methods of Using Thereof EFTUD2, DDX21, SNRPE CA2 4173/4885CAMK2A 3105/4885AKR1B1 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.